Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

[PMS] LINZESS® Tablet 0.25mg Long-term Specified Drug Use-results Survey in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)

NCT03471728 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT03471728
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03471728 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
[PMS] LINZESS® Tablet 0.25mg Long-term Specified Drug Use-results Survey in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)
Lead sponsor
Astellas Pharma Inc
Phase
Observational
Overall status
Completed
Start date
October 2, 2017
Completion date
December 31, 2021
Enrollment
2,475 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

chronic constipation (cc) (excluding constipation due to organic diseases), irritable bowel syndrome with constipation (ibs-c)